Drug intelligence / Profile preview

atorvastatin + donepezil

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination of atorvastatin (a statin medication) and donepezil (an acetylcholinesterase inhibitor). This combination was specifically studied in the LEADe (Lipitor's Effect in Alzheimer's Dementia) trial to test whether adding atorvastatin 80 mg daily would provide benefits for patients with mild to moderate Alzheimer's disease who were already receiving donepezil 10 mg daily as background therapy. The study found no significant differences in cognition or global function compared to donepezil alone.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)Acetylcholinesterase

Beyond the preview

Go deeper on atorvastatin + donepezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atorvastatin + donepezil.

Explore the full profile